Latest 10-Q quarterly reports

ESS Tech, Inc. reported a dramatic 97% decrease in revenue for the three months ended June 30, 2026, alongside significant operating losses and a stark warning about its ability to continue as a going concern.

Mobile Infrastructure Corporation's Q2 2026 10-Q filing reveals continued net losses and significant debt, raising substantial doubt about its ability to continue as a going concern.

Codexis, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting an increase in product revenue but a continued net loss, alongside a significant decrease in cash and cash equivalents.

AtaiBeckley Inc. has entered into a merger agreement with Eli Lilly and Company for an acquisition valued at $6.75 per share plus contingent value rights, while reporting Q2 2026 results with increased R&D expenses and continued net losses.

Snail Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a net loss of $3.04 million and ongoing challenges with Nasdaq listing requirements.

Inhibikase Therapeutics, Inc. (IKT) filed its Q2 2026 10-Q, detailing increased R&D expenses, a substantial net loss of $19.6 million for the quarter, and highlighting the critical need for future capital raises to sustain operations.

Waters Corporation's Q2 2026 10-Q filing reveals a significant net loss and increased debt, largely due to the recent BDS Business Acquisition, despite substantial revenue growth.

Tandy Leather Factory, Inc. (TLF) reported a 1.5% increase in net sales for Q2 2026, driven by sales campaigns and improved product mix, alongside a significant 10.6% rise in gross profit due to pricing adjustments.

Highview Merger Corp. reports on its financial condition and operational status for the quarter ended June 30, 2026, highlighting interest income and ongoing efforts to identify a business combination target.

Aramark's Q3 2026 filing shows a significant increase in revenue and operating income, driven by strong performance in both domestic and international segments, despite some cost pressures.

Factorial Energy Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and operational expenses as it advances its solid-state battery technology.

Autolus Therapeutics plc announced significant revenue growth in the second quarter of 2026, primarily driven by increased sales of its AUCATZYL therapy in the US and UK.

Lenz Therapeutics announced its second-quarter 2026 financial results, highlighting initial product sales for VIZZ but also a substantial increase in operating expenses and continued net losses.

Fold Holdings, Inc. reported a 26% year-over-year revenue decrease for Q2 2026, driven by a downturn in digital asset markets, alongside significant operating losses and a material weakness in internal controls.

Interface Inc. announced a 5.4% increase in Q2 2026 net sales to $395.7 million and a significant rise in net income to $51.4 million, driven by higher demand and improved margins.

EBR Systems, Inc. reported increased net sales for Q2 2026, but also disclosed substantial doubt about its ability to continue as a going concern, despite FDA approval of its WiSE CRT System.

BridgeBio Oncology Therapeutics, Inc. reported increased operating expenses and net losses for the second quarter of 2026, driven by expanded research and development activities for its lead product candidates.

Neutron Holdings, Inc. (Lime) reported strong revenue growth and a significant turnaround in net income following its IPO, driven by fleet expansion and increased ridership.

Global Arena Holding, Inc. filed its Q3 2025 10-Q, showing increased revenues but also persistent operating losses and a substantial accumulated deficit, raising going concern doubts.

Immunome, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses and net losses, alongside progress in its oncology therapy pipeline.

Energy Vault Holdings, Inc. announced its second quarter 2026 financial results, showing a substantial increase in revenue driven by energy storage product sales and tolling agreements, but also reporting continued net losses and increased debt.

NextNav Inc. filed its Q2 2026 quarterly report, detailing continued net losses and operational expenses, alongside significant cash inflows from warrant exercises.

Absci Corporation's Q2 2026 filing reveals a widening net loss and increased R&D expenses, though positive interim data for its lead candidate ABS-201 offers a glimmer of progress.

Anterix Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in net income driven by a significant reduction in non-cash gains from intangible asset exchanges compared to the prior year, alongside improved operating cash flow and continued customer contract activity.

Pliant Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and operational adjustments, while advancing its PLN-101095 oncology program.

Gain Therapeutics reported continued net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, even as its lead Parkinson's drug candidate, rexaceract, progresses through clinical trials.

Hoyne Bancorp, Inc. reported a slight decrease in net income for Q2 2026 compared to Q2 2025, driven by increased noninterest expenses, though net interest income saw improvement.

Dermata Therapeutics reports a net loss of $2.97 million for Q2 2026, faces going concern uncertainty, and is engaged in significant litigation with a former licensor, while preparing for its Tome skincare product launch.

Kyverna Therapeutics announced a First Amendment to its Loan and Security Agreement, extending loan availability and outlining new covenants, while also providing updates on its CAR T therapies for autoimmune diseases.

IZEA Worldwide's Q2 2026 filing reveals a 36% year-over-year revenue decrease, driven by a strategic shift and market softness, resulting in a net loss.